🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Pre-Open Movers: Akero Doubles on Drug Data, Tech Stocks Fall on Hot CPI

Published 13-09-2022, 06:26 pm
© Reuters.
MSFT
-
GOOGL
-
AAPL
-
TSN
-
NFLX
-
MANT
-
CPRX
-
META
-
LNG
-
RVNC
-
AKRO
-
PTON
-
U
-
APP
-
RENT
-
BRZE
-
PL
-

Pre-Open Stock Movers:

Akero Therapeutics, Inc. (Nasdaq: NASDAQ:AKRO) 125% HIGHER; released topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), fibrosis stage 2 or 3 (F2-F3). The study met its primary endpoint for both the 50mg and 28mg EFX dose groups, with 41% and 39% of EFX-treated patients, respectively, experiencing at least a one-stage improvement in liver fibrosis with no worsening of NASH by week 24, compared with 20% for the placebo arm.

Rent the Runway (RENT) 23% LOWER; reported Q2 EPS of ($0.53), $0.12 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $76.5 million versus the consensus estimate of $73.57 million. Rent the Runway sees Q3 2022 revenue of $72-74 million, versus the consensus of $79.7 million. Rent the Runway sees FY2022 revenue of $285-290 million, versus the consensus of $303.84 million.

Planet Labs (PL) 11% HIGHER; reported Q2 EPS of ($0.15), $0.01 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $48.5 million versus the consensus estimate of $42.4 million. Planet Labs sees Q3 2023 revenue of $45-48 million, versus the consensus of $46.6 million. Planet Labs sees FY2023 revenue of $182-190 million, versus the consensus of $182 million.

Catalyst Pharmaceuticals Inc. (CPRX) 7% HIGHER; will replace Mantech International Corp. (MANT) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, September 15.

Revance Therapeutics, Inc. (Nasdaq: NASDAQ:RVNC) 7% LOWER; Announced the pricing of an upsized underwritten public offering of 8,000,000 shares of its common stock. The shares of common stock are being offered at a public offering price of $25.00 per share

Braze, Inc. (BRZE) 7% LOWER; reported Q2 EPS of ($0.16), $0.04 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $86.1 million versus the consensus estimate of $81.16 million. Braze, Inc. sees Q3 2023 EPS of ($0.22)-($0.23), versus the consensus of ($0.20). Braze, Inc. sees Q3 2023 revenue of $90-91 million, versus the consensus of $90.3 million. Braze, Inc. sees FY2023 EPS of ($0.77)-($0.79), versus the consensus of ($0.80). Braze, Inc. sees FY2023 revenue of $347-350 million, versus the consensus of $346.83 million.

Unity Software Inc. (U) 7% LOWER; AppLovin (APP) announced that it does not intend to submit another proposal to combine with Unity Software Inc. (U) and has withdrawn its initial proposal from August 9, 2022.

Peloton Interactive, Inc. (NASDAQ:PTON) 5% LOWER; accepted the resignations of John Foley as Executive Chair and Hisao Kushi as Chief Legal Officer, effective September 12, 2022 and October 3, 2022, respectively.

Netflix, Inc. (NASDAQ:NFLX) 4% LOWER; tech stocks fall on hot CPI

Alphabet Inc. (NASDAQ:GOOGL) 3% LOWER; tech stocks fall on hot CPI

Meta Platforms, Inc. (META) 3% LOWER; tech stocks fall on hot CPI

Tyson (TSN) 2% LOWER; Argus downgraded from Buy to Hold.

Apple Inc. (NASDAQ:AAPL) 2% LOWER; tech stocks fall on hot CPI

Microsoft Corporation (NASDAQ:MSFT) 2% LOWER; tech stocks fall on hot CPI

Cheniere Energy Inc . (NYSE:LNG) 1% HIGHER; lifted its full-year 2022 profit forecast above consensus.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.